Amanda Gillon
Investment Analyst @ BioScience Managers Limited
Melbourne, Australia
Amanda Gillon is a post-ipo equity investor at BioScience Managers Limited in Melbourne focused on Medical and Wellness. Amanda has over seven years of life science experience with close familiarity with plant biotechnology and human protein folding diseases.She holds a PhD in Molecular Biology and Biochemistry from La Trobe University together with the agri-biotechnology company Hexima Ltd., focusing on a family of novel circular proteins (cyclotides) thatpossess potent biopharmaceutical properties.Since completing her PhD, Amanda worked for three years as a research scientist at Columbia University in New York City identifying new genetic and biochemical pathways that may be directly relevant to a number of human diseases, most notably cystic fibrosis. Amanda has recently been involved in a number of biotechnology commercialization groups.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Amanda Gillon invests in
Stages Amanda Gillon invests in
Countries Amanda Gillon invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (100%)
- Wellness 1 (100%)
- Health Care 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Adherium (previously known as Nexus6) is a privately owned developer and manufacturer of solutions that help patients and their healthcare professionals monitor and increase patient adherence to prescribed therapies, leading to improved disease management and reduced healthcare costs. | $3.3M / Post-IPO Equity / May 26, 2020 |
Co-Investors
BioScience Managers Pty Ltd (formerly IB Managers) is a leading life sciences investment firm, headquartered in Melbourne, Australia. Established in 2003, BioScience Managers offers a global, multi-disciplinary team, bringing an international perspective together with the track record, networks and expertise required to convert that perspectiveinto informed, high return investment decisions.We operate a high value-add model, providing assistance and support to portfolio companies via our global team and international network of independent industry advisors. With combined experience of over 170 investments, more than 40 IPO’s/ reversals in Europe, the USA and Australia, and a diverse skillset specific to the bio-based industries, we aim to provide investee companies with significant value-add over and above capital invested.Alongside our funds management business, Phillip Bioscience Advisory provides specialist corporate advisory services to healthcare and life sciences companies.
BioScience Managers Limited Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Amanda Gillon
Investment Analyst
|
|||
Matt McNamara
Managing Director
|
|||
Nora Frey
Investment Manager
|
|||
Bronwyn Dilley
senior executive
|
|||
Jeremy Curnock Cook
Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Amanda Gillon invest in?
Amanda Gillon invests primarily in Medical, Wellness and Health Care startups, most often at Post-IPO Equity stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Amanda Gillon?
Public channels for Amanda Gillon include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Amanda Gillon last invest?
The most recent investment recorded for Amanda Gillon closed in May 2020. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
